BACKGROUND: Hyperglycemia has been associated with increased inflammatory indexes and larger infarct sizes in patients with obstructive acute myocardial infarction (obs-AMI). In contrast, no studies have explored these correlations in non-obstructive acute myocardial infarction (MINOCA). We investigated the relationship between hyperglycemia, inflammation and infarct size in a cohort of AMI patients that included MINOCA. METHODS: Patients with AMI undergoing coronary angiography between 2016 and 2020 were enrolled. The following inflammatory markers were evaluated: C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and neutrophil-to-platelet ratio (NPR). Myocardial infarct size was measured by peak high sensitivity troponin I (Hs-TnI) levels, left-ventricular-end-diastolic-volume (LVEDV) and left ventricular ejection fraction (LVEF). RESULTS: The final study population consisted of 2450 patients with obs-AMI and 239 with MINOCA. Hyperglycemia was more prevalent among obs-AMI cases. In all hyperglycemic patients-obs-AMI and MINOCA-NLR, NPR, and LPR were markedly altered. Hyperglycemic obs-AMI subjects exhibited a higher Hs-TnI (p < 0.001), a larger LVEDV (p = 0.003) and a lower LVEF (p < 0.001) compared to normoglycemic ones. Conversely, MINOCA patients showed a trivial myocardial damage, irrespective of admission glucose levels. CONCLUSIONS: Our data confirm the association of hyperglycemic obs-AMI with elevated inflammatory markers and larger infarct sizes. MINOCA patients exhibited modest myocardial damage, regardless of admission glucose levels.
BACKGROUND:Hyperglycemia has been associated with increased inflammatory indexes and larger infarct sizes in patients with obstructive acute myocardial infarction (obs-AMI). In contrast, no studies have explored these correlations in non-obstructive acute myocardial infarction (MINOCA). We investigated the relationship between hyperglycemia, inflammation and infarct size in a cohort of AMI patients that included MINOCA. METHODS:Patients with AMI undergoing coronary angiography between 2016 and 2020 were enrolled. The following inflammatory markers were evaluated: C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and neutrophil-to-platelet ratio (NPR). Myocardial infarct size was measured by peak high sensitivity troponin I (Hs-TnI) levels, left-ventricular-end-diastolic-volume (LVEDV) and left ventricular ejection fraction (LVEF). RESULTS: The final study population consisted of 2450 patients with obs-AMI and 239 with MINOCA. Hyperglycemia was more prevalent among obs-AMI cases. In all hyperglycemic patients-obs-AMI and MINOCA-NLR, NPR, and LPR were markedly altered. Hyperglycemic obs-AMI subjects exhibited a higher Hs-TnI (p < 0.001), a larger LVEDV (p = 0.003) and a lower LVEF (p < 0.001) compared to normoglycemic ones. Conversely, MINOCA patients showed a trivial myocardial damage, irrespective of admission glucose levels. CONCLUSIONS: Our data confirm the association of hyperglycemic obs-AMI with elevated inflammatory markers and larger infarct sizes. MINOCA patients exhibited modest myocardial damage, regardless of admission glucose levels.
Authors: O Collste; P Sörensson; M Frick; S Agewall; M Daniel; L Henareh; C Ekenbäck; L Eurenius; C Guiron; T Jernberg; C Hofman-Bang; K Malmqvist; E Nagy; H Arheden; P Tornvall Journal: J Intern Med Date: 2012-08-05 Impact factor: 8.989
Authors: Jacob Lønborg; Niels Vejlstrup; Henning Kelbæk; Lars Nepper-Christensen; Erik Jørgensen; Steffen Helqvist; Lene Holmvang; Kari Saunamäki; Hans Erik Bøtker; Won Yong Kim; Peter Clemmensen; Marek Treiman; Thomas Engstrøm Journal: Diabetes Date: 2014-02-28 Impact factor: 9.461
Authors: Shu-Hua Mi; Gong Su; Hong-Xia Yang; Yun Zhou; Lei Tian; Tao Zhang; Hong Tao Journal: Diabetol Metab Syndr Date: 2017-03-21 Impact factor: 3.320
Authors: Chen Chen; Bai Lin Cong; Min Wang; Muhammad Abdullah; Xiao Long Wang; Yin Hua Zhang; Shun Ji Xu; Lan Cui Journal: Integr Med Res Date: 2018-03-08
Authors: M A Beijk; W V Vlastra; R Delewi; T P van de Hoef; S M Boekholdt; K D Sjauw; J J Piek Journal: Neth Heart J Date: 2019-05 Impact factor: 2.380
Authors: Patric Winzap; Allan Davies; Roland Klingenberg; Slayman Obeid; Marco Roffi; François Mach; Lorenz Räber; Stephan Windecker; Christian Templin; Fabian Nietlispach; David Nanchen; Baris Gencer; Olivier Muller; Christian M Matter; Arnold von Eckardstein; Thomas F Lüscher Journal: Cardiovasc Diabetol Date: 2019-10-31 Impact factor: 9.951
Authors: Nathaniel R Smilowitz; Rachel Dubner; Anne S Hellkamp; Robert J Widmer; Harmony R Reynolds Journal: PLoS One Date: 2021-08-02 Impact factor: 3.240